News
Access free, up-to-date clinical references on the presentation, diagnosis and assessment of non-small cell lung cancer at Healio. Clinical Guidance content provides valuable insights for physicians.
FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on ...
Background. Weight loss is a common symptom in patients with lung cancer and mesothelioma. Previous studies have suggested that weight loss at presentation may predict chemotherapy treatment ...
In this presentation, I will demonstrate how our lab is developing innovative methods to better detect and study tumor-reactive TIL in the context of resectable lung cancers. Learning Objectives: 1.
AbbVie (NYSE: ABBV) today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical ...
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 Provided by Business Wire Mar 25, 2025, 12:46:00 PM.
AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR ...
I was a runner and ‘never smoker’ — then I got diagnosed with lung cancer at 28 By . Tracy Swartz. Published May 16, 2025, 6:00 a.m. ET. Deep breath!
A cancer patient who was ready to fly halfway across the country for a potentially life-saving double lung transplant has said he was denied insurance coverage at the last second. Married father ...
Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation ...
Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer ...
Poster (1358P): Plinabulin/Docetaxel Versus Docetaxel in Survival Benefits of 2L/3L EGFR Wild-Type NSCLC after Platinum Regimens (DUBLIN-3): a Randomized Phase 3 Trial Dublin-3 NSCLC was a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results